# A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

> **NCT05947851** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 735 (estimated)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Chronic Lymphocytic
- Small-Cell Lymphoma
- Lymphoma, Small Lymphocytic
- CLL
- SLL

## Interventions

- **DRUG:** Nemtabrutinib
- **DRUG:** Venetoclax
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT05947851
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-08
- **Primary completion:** 2032-06-01
- **Final completion:** 2035-07-01
- **Target enrollment:** 735 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947851, "A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05947851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*